Treatment of advanced colorectal carcinoma with AMSA

AMSA in a dose of 120 mg/m2 iv every 4 weeks was evaluated in 26 patients with advanced measurable colorectal cancer, 13 of whom had had no prior chemotherapy. The schedule was tolerated well except by those patients who had prior irradiation or chemotherapy, in whom a dose reduction to 90 mg/m2 was required. No significant antitumor response was observed.